CD8A and neoplasm: CD8α+ cDCs are specialized in cross presentation of Ags via MHC class I to CTLs, and therefore enhancing CD8α+ cDC activation for tumor vaccine has been demonstrated as a new promising strategy in vaccine development [22–24].